2023 Fiscal Year Final Research Report
Cancer cell division based on the abnormal phosphorylation signaling
| Project/Area Number |
21K15263
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 47030:Pharmaceutical hygiene and biochemistry-related
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | がん細胞分裂 / リン酸化シグナル / アミノ酸輸送体 / がん特異的治療法 |
|---|
| Outline of Final Research Achievements |
The number of cancer patients is expected to continue to increase with the aging of the population; therefore, developing new cancer treatments is an urgent issue. In cancer chemotherapy, anticancer drugs that target the cell division process have been clinically used, and new drug development is still underway. In this study, we hypothesized and examined that cancer cells have a unique division pattern. We searched for mitogenic molecules through siRNA screening of cancer cells and identified SH2D4A and LAT1 as a candidate molecule, and we could reveal those roles in cancer cell division.
|
| Free Research Field |
がん生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
がん細胞分裂を標的とする治療法は、タキサン系薬剤やビンカアルカロイド系薬剤の治療実績からも重要性が示されてきた。しかし、副作用として末梢神経障害や消化管障害などが懸念されており、十分な投薬継続が実施できていない症例も多い。そのため、がん細胞特異的に分裂を阻害する治療法の確立が求められる。本研究の遂行によって、SH2D4AやLAT1をがん細胞分裂支持因子として同定することができた。本研究を基に、分裂標的薬との併用による効果的な治療に資することが期待される。
|
